A FIRST-IN-HUMAN, PHASE I, DOSE-ESCALATION STUDY OF TAK-117, A SELECTIVE PI3KΑ ISOFORM INHIBITOR, IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES

Wednesday, July 26, 2017

Read the Story Here

Related Posts

Discover more posts like this.

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Oct 25, 2024

Dr. Minal Barve

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial

Oct 14, 2024

Dr. Minal Barve

First-in-human Phase 1/2a Trial of a Macrocyclic ATR inhibitor (ATRN-119) in Patients with Advanced Solid Tumors.

Oct 2, 2024

Dr. Reva Schneider
See All Posts